Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
pH maintenance, Spermicide, Microbicide Lubricant More
rHu G-CSF More
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. More
The present technology describes recombinant poxvirus vectors encoding at least three or more costimulatory molecules and TAAs. More
A novel selective antimicrobial peptide based on human LL-37 by D-amino acid incorporation. More
Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Academics at the University of Nottingham have invented a new method to inactivate viruses without affecting valuable blood and plasma proteins. More
Compositions and methods for improving the growth characteristics of cells engineered to produce biologically active products such as antibodies or glycosylated proteins. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Aspergillosis
- Bronchitis
- Candidiasis
- Chicken pox
- Chlamydia
- Cholera
- Chronic fatigue syndrome
- Creutzfeldt-Jakob disease
- Diarrhea, bacterial
- Diphtheria
- Ebola hemorrhagic fever
- Encephalitis
- Epstein-Barr virus
- Fever
- Food poisoning
- Gastroenteritis
- Genital warts
- German measles
- Gonorrhea
- Hepatitis A/B
- Hepatitis C/D/E
- HIV
- Infection, bacterial(other)
- Infection, fungal (other)
- Infection, viral (other)
- Infectious disease (other)
- Influenza
- Legionnaire's disease
- Leprosy
- Lyme disease
- Malaria
- Measles
- Meningitis, bacterial
- Meningitis, cryptococcal
- Meningitis, neoplastic
- Meningitis, viral
- Mumps
- Pneumonia
- Polio
- Protozoal diseases (other)
- Pseudomonas lung infection
- Rabies
- Rhinovirus (common cold)
- Rotavirus infection
- Sepsis
- Shingles
- Sinusitis
- Streptococcal infections
- Tetanus
- Trypanosomiasis
- Tuberculosis
- Typhoid
- Urinary tract infection
- Warts
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us